Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Stroke | 73 | 2021 | 1127 | 10.450 |
Why?
|
Ischemic Attack, Transient | 14 | 2019 | 90 | 4.930 |
Why?
|
Brain Ischemia | 26 | 2020 | 399 | 3.980 |
Why?
|
Fibrinolytic Agents | 15 | 2020 | 163 | 2.350 |
Why?
|
Tissue Plasminogen Activator | 16 | 2020 | 125 | 2.160 |
Why?
|
Thrombolytic Therapy | 11 | 2020 | 184 | 1.560 |
Why?
|
Cerebral Hemorrhage | 8 | 2021 | 85 | 1.490 |
Why?
|
Atrial Fibrillation | 11 | 2020 | 805 | 1.400 |
Why?
|
Stroke Rehabilitation | 5 | 2021 | 46 | 1.310 |
Why?
|
Brain | 14 | 2024 | 1488 | 1.290 |
Why?
|
Humans | 108 | 2025 | 59360 | 1.180 |
Why?
|
Secondary Prevention | 4 | 2017 | 151 | 1.100 |
Why?
|
Middle Cerebral Artery | 4 | 2017 | 46 | 1.090 |
Why?
|
Hypertension | 8 | 2017 | 568 | 1.070 |
Why?
|
Aged | 50 | 2021 | 13416 | 1.000 |
Why?
|
Thrombectomy | 2 | 2019 | 208 | 0.990 |
Why?
|
Antihypertensive Agents | 4 | 2016 | 162 | 0.940 |
Why?
|
Cell-Free Nucleic Acids | 1 | 2024 | 11 | 0.910 |
Why?
|
Cerebrovascular Disorders | 4 | 2018 | 74 | 0.900 |
Why?
|
Female | 62 | 2021 | 30705 | 0.890 |
Why?
|
Organoids | 1 | 2024 | 40 | 0.890 |
Why?
|
Platelet Aggregation Inhibitors | 8 | 2014 | 211 | 0.870 |
Why?
|
Male | 56 | 2021 | 27739 | 0.840 |
Why?
|
Motor Neuron Disease | 1 | 2023 | 28 | 0.830 |
Why?
|
Hematoma | 3 | 2019 | 68 | 0.800 |
Why?
|
Heart Septal Defects, Atrial | 2 | 2016 | 8 | 0.790 |
Why?
|
Blood Pressure | 3 | 2016 | 495 | 0.750 |
Why?
|
Middle Aged | 46 | 2021 | 16317 | 0.740 |
Why?
|
Treatment Outcome | 28 | 2020 | 5284 | 0.720 |
Why?
|
Endovascular Procedures | 3 | 2016 | 608 | 0.710 |
Why?
|
Emergency Medical Services | 2 | 2014 | 255 | 0.680 |
Why?
|
Aged, 80 and over | 24 | 2021 | 5128 | 0.670 |
Why?
|
Bed Rest | 1 | 2019 | 10 | 0.670 |
Why?
|
Myxoma | 1 | 2019 | 13 | 0.660 |
Why?
|
Risk Factors | 25 | 2020 | 4984 | 0.660 |
Why?
|
Tomography, X-Ray Computed | 13 | 2016 | 1526 | 0.640 |
Why?
|
Severity of Illness Index | 13 | 2019 | 1479 | 0.630 |
Why?
|
Time Factors | 22 | 2020 | 3617 | 0.630 |
Why?
|
Retrospective Studies | 22 | 2020 | 6071 | 0.630 |
Why?
|
Piperazines | 3 | 2025 | 74 | 0.620 |
Why?
|
Telemedicine | 2 | 2023 | 307 | 0.620 |
Why?
|
Carotid Stenosis | 4 | 2014 | 104 | 0.610 |
Why?
|
Electrocardiography, Ambulatory | 2 | 2017 | 40 | 0.600 |
Why?
|
Magnetic Resonance Imaging | 13 | 2021 | 2060 | 0.590 |
Why?
|
Infarction, Middle Cerebral Artery | 2 | 2017 | 70 | 0.580 |
Why?
|
Emergency Service, Hospital | 2 | 2016 | 1021 | 0.560 |
Why?
|
Concurrent Review | 1 | 2017 | 3 | 0.560 |
Why?
|
Length of Stay | 4 | 2020 | 775 | 0.560 |
Why?
|
Triage | 2 | 2016 | 109 | 0.550 |
Why?
|
Ticlopidine | 2 | 2014 | 45 | 0.540 |
Why?
|
Endocarditis, Bacterial | 1 | 2016 | 31 | 0.530 |
Why?
|
Teaching | 2 | 2008 | 152 | 0.530 |
Why?
|
Virtual Reality | 1 | 2016 | 12 | 0.520 |
Why?
|
Thalamic Diseases | 1 | 2016 | 2 | 0.520 |
Why?
|
Primary Prevention | 1 | 2017 | 134 | 0.510 |
Why?
|
Spondylitis, Ankylosing | 1 | 2016 | 24 | 0.500 |
Why?
|
Aspirin | 2 | 2014 | 166 | 0.500 |
Why?
|
Practice Patterns, Physicians' | 2 | 2020 | 687 | 0.490 |
Why?
|
Postmenopause | 4 | 2021 | 224 | 0.470 |
Why?
|
Quality of Health Care | 2 | 2020 | 510 | 0.460 |
Why?
|
Feedback, Psychological | 1 | 2014 | 11 | 0.460 |
Why?
|
Occupational Therapy | 1 | 2014 | 12 | 0.450 |
Why?
|
Speech Therapy | 1 | 2014 | 15 | 0.450 |
Why?
|
Physical Therapy Modalities | 1 | 2014 | 45 | 0.440 |
Why?
|
Dipyridamole | 1 | 2013 | 17 | 0.440 |
Why?
|
Smoking | 4 | 2018 | 826 | 0.440 |
Why?
|
Anti-Bacterial Agents | 2 | 2016 | 735 | 0.430 |
Why?
|
Endarterectomy, Carotid | 2 | 2012 | 91 | 0.430 |
Why?
|
Spinocerebellar Ataxias | 1 | 2013 | 10 | 0.430 |
Why?
|
Healthcare Disparities | 3 | 2020 | 326 | 0.420 |
Why?
|
Interprofessional Relations | 1 | 2014 | 129 | 0.420 |
Why?
|
Coronavirus Infections | 3 | 2020 | 192 | 0.410 |
Why?
|
Pneumonia, Viral | 3 | 2020 | 205 | 0.410 |
Why?
|
Dementia, Multi-Infarct | 1 | 2012 | 4 | 0.410 |
Why?
|
Encephalitis, Varicella Zoster | 1 | 2012 | 2 | 0.410 |
Why?
|
Quality Improvement | 1 | 2017 | 416 | 0.400 |
Why?
|
Cocaine-Related Disorders | 1 | 2013 | 82 | 0.400 |
Why?
|
Intracranial Aneurysm | 1 | 2016 | 345 | 0.400 |
Why?
|
Diffusion Magnetic Resonance Imaging | 7 | 2020 | 145 | 0.400 |
Why?
|
Intracranial Hemorrhages | 3 | 2020 | 61 | 0.400 |
Why?
|
Sulfones | 2 | 2009 | 36 | 0.390 |
Why?
|
Recovery of Function | 7 | 2020 | 270 | 0.390 |
Why?
|
Hospital Units | 1 | 2011 | 8 | 0.390 |
Why?
|
Cohort Studies | 7 | 2019 | 2374 | 0.380 |
Why?
|
Leukoaraiosis | 3 | 2019 | 44 | 0.380 |
Why?
|
Colonoscopy | 1 | 2012 | 86 | 0.370 |
Why?
|
Brain Damage, Chronic | 1 | 2011 | 5 | 0.370 |
Why?
|
Inpatients | 1 | 2014 | 291 | 0.370 |
Why?
|
Hospitals | 1 | 2014 | 375 | 0.360 |
Why?
|
Vertebrobasilar Insufficiency | 2 | 2012 | 23 | 0.360 |
Why?
|
Stents | 2 | 2013 | 461 | 0.350 |
Why?
|
Internship and Residency | 2 | 2008 | 746 | 0.340 |
Why?
|
Educational Measurement | 2 | 2008 | 211 | 0.320 |
Why?
|
Cerebral Cortex | 1 | 2011 | 248 | 0.320 |
Why?
|
Neurology | 3 | 2020 | 33 | 0.320 |
Why?
|
Troponin | 2 | 2019 | 36 | 0.320 |
Why?
|
Anticoagulants | 4 | 2019 | 477 | 0.320 |
Why?
|
Mortality | 2 | 2021 | 155 | 0.310 |
Why?
|
Prognosis | 7 | 2020 | 1600 | 0.310 |
Why?
|
Neurophysiology | 1 | 2008 | 7 | 0.300 |
Why?
|
Clinical Medicine | 1 | 2008 | 15 | 0.300 |
Why?
|
Video Games | 1 | 2008 | 12 | 0.300 |
Why?
|
Embolism, Paradoxical | 1 | 2008 | 13 | 0.300 |
Why?
|
Foramen Ovale, Patent | 1 | 2008 | 13 | 0.290 |
Why?
|
Mass Screening | 1 | 2013 | 645 | 0.290 |
Why?
|
Intracranial Embolism | 3 | 2017 | 39 | 0.280 |
Why?
|
Young Adult | 6 | 2019 | 4267 | 0.280 |
Why?
|
Recurrence | 4 | 2016 | 603 | 0.280 |
Why?
|
Spinal Puncture | 1 | 2007 | 15 | 0.270 |
Why?
|
Acute Disease | 3 | 2014 | 660 | 0.270 |
Why?
|
Continuous Positive Airway Pressure | 1 | 2007 | 30 | 0.270 |
Why?
|
Whole Genome Sequencing | 2 | 2024 | 63 | 0.270 |
Why?
|
Brain Stem Infarctions | 1 | 2006 | 4 | 0.260 |
Why?
|
Needles | 1 | 2007 | 65 | 0.260 |
Why?
|
Pons | 1 | 2006 | 15 | 0.260 |
Why?
|
Quadriplegia | 1 | 2006 | 14 | 0.260 |
Why?
|
Smoking Cessation | 3 | 2018 | 541 | 0.260 |
Why?
|
Sleep Apnea, Obstructive | 1 | 2007 | 54 | 0.260 |
Why?
|
Magnetic Resonance Angiography | 4 | 2016 | 178 | 0.260 |
Why?
|
Age Factors | 6 | 2020 | 1504 | 0.250 |
Why?
|
Ventricular Function, Left | 2 | 2018 | 257 | 0.250 |
Why?
|
Predictive Value of Tests | 7 | 2020 | 1025 | 0.250 |
Why?
|
Ultrasonography, Doppler, Transcranial | 2 | 2016 | 21 | 0.250 |
Why?
|
Piracetam | 1 | 2005 | 8 | 0.250 |
Why?
|
Hyponatremia | 1 | 2005 | 13 | 0.240 |
Why?
|
Logistic Models | 7 | 2018 | 1232 | 0.240 |
Why?
|
Pandemics | 4 | 2023 | 615 | 0.240 |
Why?
|
Hospitalization | 4 | 2020 | 1290 | 0.240 |
Why?
|
Anticonvulsants | 1 | 2005 | 88 | 0.230 |
Why?
|
Clinical Protocols | 1 | 2005 | 135 | 0.230 |
Why?
|
Thalamus | 2 | 2016 | 64 | 0.230 |
Why?
|
Curriculum | 1 | 2008 | 558 | 0.220 |
Why?
|
Betacoronavirus | 3 | 2020 | 166 | 0.220 |
Why?
|
Epilepsy | 1 | 2005 | 105 | 0.220 |
Why?
|
Hypercholesterolemia | 2 | 2014 | 68 | 0.220 |
Why?
|
Heart Atria | 2 | 2017 | 135 | 0.210 |
Why?
|
Cerebral Angiography | 4 | 2017 | 280 | 0.210 |
Why?
|
Neoplasm Proteins | 1 | 2025 | 277 | 0.210 |
Why?
|
Adult | 13 | 2019 | 15669 | 0.200 |
Why?
|
National Institute of Neurological Disorders and Stroke (U.S.) | 2 | 2020 | 7 | 0.200 |
Why?
|
Ischemia | 2 | 2019 | 199 | 0.200 |
Why?
|
Purpura, Thrombotic Thrombocytopenic | 1 | 2022 | 8 | 0.200 |
Why?
|
Carotid Artery, Common | 1 | 2002 | 30 | 0.190 |
Why?
|
United States | 10 | 2020 | 7390 | 0.190 |
Why?
|
Health Services Needs and Demand | 2 | 2020 | 203 | 0.190 |
Why?
|
Rehabilitation Centers | 1 | 2021 | 12 | 0.190 |
Why?
|
Carotid Artery Diseases | 1 | 2002 | 63 | 0.190 |
Why?
|
Venous Thromboembolism | 2 | 2014 | 141 | 0.180 |
Why?
|
Eggs | 1 | 2021 | 7 | 0.180 |
Why?
|
Multivariate Analysis | 6 | 2018 | 902 | 0.180 |
Why?
|
Cerebral Amyloid Angiopathy | 1 | 2021 | 3 | 0.180 |
Why?
|
Oxygen | 2 | 2014 | 313 | 0.180 |
Why?
|
Genetic Loci | 1 | 2021 | 107 | 0.180 |
Why?
|
Biomarkers | 2 | 2024 | 1306 | 0.180 |
Why?
|
Cholesterol, Dietary | 1 | 2021 | 28 | 0.180 |
Why?
|
Incidence | 6 | 2020 | 1237 | 0.180 |
Why?
|
Clinical Trials as Topic | 2 | 2016 | 441 | 0.180 |
Why?
|
Skilled Nursing Facilities | 1 | 2021 | 83 | 0.180 |
Why?
|
Myocardial Infarction | 3 | 2019 | 862 | 0.180 |
Why?
|
Risk Assessment | 6 | 2020 | 1921 | 0.180 |
Why?
|
Precision Medicine | 1 | 2021 | 102 | 0.170 |
Why?
|
Databases, Factual | 4 | 2020 | 813 | 0.170 |
Why?
|
Noncommunicable Diseases | 1 | 2020 | 15 | 0.170 |
Why?
|
Patient Discharge | 2 | 2021 | 489 | 0.170 |
Why?
|
Drug Administration Schedule | 2 | 2012 | 283 | 0.170 |
Why?
|
Time-to-Treatment | 1 | 2020 | 98 | 0.170 |
Why?
|
Cost-Benefit Analysis | 2 | 2011 | 297 | 0.170 |
Why?
|
Phosphodiesterase Inhibitors | 3 | 2009 | 27 | 0.160 |
Why?
|
Thrombosis | 1 | 2002 | 182 | 0.160 |
Why?
|
Retinal Artery Occlusion | 1 | 2019 | 5 | 0.160 |
Why?
|
Cyclic GMP | 3 | 2009 | 28 | 0.160 |
Why?
|
Vitamin K | 1 | 2019 | 14 | 0.160 |
Why?
|
Heart Neoplasms | 1 | 2019 | 31 | 0.160 |
Why?
|
Antineoplastic Agents | 1 | 2025 | 631 | 0.160 |
Why?
|
Prospective Studies | 7 | 2021 | 3067 | 0.160 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2021 | 439 | 0.160 |
Why?
|
Global Health | 1 | 2020 | 167 | 0.160 |
Why?
|
Drug Therapy, Combination | 3 | 2012 | 452 | 0.160 |
Why?
|
Sweetening Agents | 1 | 2019 | 21 | 0.160 |
Why?
|
Embolism | 1 | 2019 | 39 | 0.160 |
Why?
|
Neurodegenerative Diseases | 1 | 2021 | 134 | 0.160 |
Why?
|
Mechanical Thrombolysis | 1 | 2019 | 35 | 0.160 |
Why?
|
Leukoencephalopathies | 1 | 2019 | 24 | 0.150 |
Why?
|
Women's Health | 2 | 2019 | 360 | 0.150 |
Why?
|
Sex Factors | 3 | 2019 | 935 | 0.150 |
Why?
|
Spinal Cord | 2 | 2016 | 195 | 0.150 |
Why?
|
Beverages | 1 | 2019 | 66 | 0.150 |
Why?
|
Nervous System Diseases | 1 | 2020 | 104 | 0.150 |
Why?
|
Sensitivity and Specificity | 3 | 2019 | 1093 | 0.150 |
Why?
|
Sildenafil Citrate | 2 | 2009 | 11 | 0.150 |
Why?
|
Activities of Daily Living | 2 | 2019 | 289 | 0.150 |
Why?
|
Subarachnoid Hemorrhage | 2 | 2016 | 93 | 0.150 |
Why?
|
Purines | 2 | 2009 | 38 | 0.150 |
Why?
|
Genetic Predisposition to Disease | 1 | 2021 | 676 | 0.150 |
Why?
|
Rhode Island | 2 | 2016 | 97 | 0.140 |
Why?
|
Dose-Response Relationship, Drug | 3 | 2009 | 806 | 0.140 |
Why?
|
White Matter | 1 | 2019 | 114 | 0.140 |
Why?
|
Hypoalbuminemia | 1 | 2017 | 7 | 0.140 |
Why?
|
Functional Laterality | 2 | 2016 | 133 | 0.140 |
Why?
|
Radiography | 2 | 2019 | 517 | 0.140 |
Why?
|
Weight Gain | 1 | 2018 | 163 | 0.140 |
Why?
|
Demyelinating Diseases | 1 | 1997 | 16 | 0.140 |
Why?
|
Vacuoles | 1 | 1997 | 26 | 0.140 |
Why?
|
Atrial Function, Right | 1 | 2017 | 1 | 0.140 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2018 | 158 | 0.140 |
Why?
|
Surveys and Questionnaires | 2 | 2023 | 2513 | 0.140 |
Why?
|
Hospital Mortality | 5 | 2020 | 841 | 0.140 |
Why?
|
Telemetry | 1 | 2017 | 19 | 0.140 |
Why?
|
Systemic Inflammatory Response Syndrome | 1 | 2017 | 41 | 0.140 |
Why?
|
Atrial Flutter | 1 | 2017 | 21 | 0.140 |
Why?
|
Hospital Administration | 1 | 2017 | 41 | 0.140 |
Why?
|
Cardiopulmonary Resuscitation | 1 | 2018 | 85 | 0.140 |
Why?
|
Disability Evaluation | 4 | 2019 | 199 | 0.140 |
Why?
|
Stroke Volume | 1 | 2018 | 314 | 0.140 |
Why?
|
Headache Disorders, Primary | 1 | 2016 | 4 | 0.130 |
Why?
|
Alcohol Abstinence | 1 | 2016 | 10 | 0.130 |
Why?
|
Random Allocation | 1 | 2017 | 192 | 0.130 |
Why?
|
Spinal Cord Diseases | 1 | 1997 | 39 | 0.130 |
Why?
|
Vasospasm, Intracranial | 1 | 2016 | 25 | 0.130 |
Why?
|
Brain Diseases | 1 | 1997 | 71 | 0.130 |
Why?
|
Heart Diseases | 1 | 2018 | 206 | 0.130 |
Why?
|
Motor Activity | 1 | 2019 | 333 | 0.130 |
Why?
|
Breast Feeding | 1 | 2018 | 143 | 0.130 |
Why?
|
Dura Mater | 1 | 2016 | 33 | 0.130 |
Why?
|
Delivery of Health Care | 1 | 2020 | 408 | 0.130 |
Why?
|
Systole | 1 | 2016 | 109 | 0.130 |
Why?
|
Carbolines | 2 | 2025 | 9 | 0.130 |
Why?
|
Heart Arrest | 1 | 2018 | 161 | 0.130 |
Why?
|
Radiography, Thoracic | 1 | 2016 | 110 | 0.120 |
Why?
|
User-Computer Interface | 1 | 2016 | 123 | 0.120 |
Why?
|
Registries | 5 | 2020 | 801 | 0.120 |
Why?
|
Heart Rate | 1 | 2017 | 307 | 0.120 |
Why?
|
Cognition | 1 | 2019 | 455 | 0.120 |
Why?
|
Aneurysm, Ruptured | 1 | 2016 | 71 | 0.120 |
Why?
|
Radionuclide Imaging | 1 | 2015 | 121 | 0.120 |
Why?
|
Cerebral Infarction | 3 | 2016 | 76 | 0.120 |
Why?
|
Decompressive Craniectomy | 1 | 2014 | 5 | 0.120 |
Why?
|
Brain Death | 1 | 2014 | 16 | 0.120 |
Why?
|
Potassium, Dietary | 1 | 2014 | 2 | 0.120 |
Why?
|
Cerebral Ventricles | 1 | 2014 | 30 | 0.120 |
Why?
|
Hospitals, Urban | 1 | 2014 | 43 | 0.120 |
Why?
|
Neoplasms | 1 | 2025 | 1240 | 0.120 |
Why?
|
Skull | 1 | 2014 | 50 | 0.120 |
Why?
|
Ultrasonography | 2 | 2010 | 459 | 0.120 |
Why?
|
Odds Ratio | 4 | 2017 | 745 | 0.120 |
Why?
|
Adolescent | 3 | 2016 | 5824 | 0.120 |
Why?
|
Ambulatory Care | 1 | 2017 | 300 | 0.120 |
Why?
|
Double-Blind Method | 3 | 2020 | 715 | 0.110 |
Why?
|
Motion Therapy, Continuous Passive | 1 | 2014 | 1 | 0.110 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2014 | 206 | 0.110 |
Why?
|
Hospital Departments | 1 | 2014 | 12 | 0.110 |
Why?
|
Comorbidity | 3 | 2020 | 1078 | 0.110 |
Why?
|
Health Literacy | 1 | 2015 | 78 | 0.110 |
Why?
|
Immunoglobulin Fab Fragments | 2 | 2004 | 36 | 0.110 |
Why?
|
Drainage | 1 | 2014 | 149 | 0.110 |
Why?
|
Quality Indicators, Health Care | 1 | 2017 | 332 | 0.110 |
Why?
|
Coloring Agents | 1 | 2014 | 53 | 0.110 |
Why?
|
Diagnostic Errors | 1 | 2014 | 95 | 0.110 |
Why?
|
Heart Failure | 2 | 2018 | 853 | 0.110 |
Why?
|
Cardiovascular Diseases | 1 | 2021 | 788 | 0.110 |
Why?
|
Alcoholism | 1 | 2016 | 309 | 0.110 |
Why?
|
Risk Reduction Behavior | 1 | 2014 | 121 | 0.110 |
Why?
|
Hyperglycemia | 1 | 2014 | 98 | 0.110 |
Why?
|
Urinary Tract Infections | 1 | 2014 | 80 | 0.110 |
Why?
|
Heparin | 1 | 2014 | 111 | 0.110 |
Why?
|
Acute Coronary Syndrome | 1 | 2016 | 250 | 0.100 |
Why?
|
Age of Onset | 1 | 2013 | 170 | 0.100 |
Why?
|
Basal Ganglia Cerebrovascular Disease | 1 | 2012 | 1 | 0.100 |
Why?
|
Pupil Disorders | 1 | 2012 | 4 | 0.100 |
Why?
|
Dysarthria | 1 | 2012 | 7 | 0.100 |
Why?
|
Apraxias | 1 | 2012 | 7 | 0.100 |
Why?
|
Acyclovir | 1 | 2012 | 19 | 0.100 |
Why?
|
Adrenal Cortex Hormones | 1 | 2014 | 169 | 0.100 |
Why?
|
Academic Medical Centers | 1 | 2014 | 306 | 0.100 |
Why?
|
Gait Disorders, Neurologic | 1 | 2012 | 17 | 0.100 |
Why?
|
Valine | 1 | 2012 | 31 | 0.100 |
Why?
|
Cyclophosphamide | 1 | 2012 | 75 | 0.100 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2014 | 202 | 0.100 |
Why?
|
Prednisone | 1 | 2012 | 85 | 0.100 |
Why?
|
Memory Disorders | 1 | 2012 | 48 | 0.100 |
Why?
|
Risk | 2 | 2010 | 364 | 0.100 |
Why?
|
Vision Disorders | 1 | 2012 | 59 | 0.100 |
Why?
|
Disease Progression | 2 | 2017 | 1122 | 0.100 |
Why?
|
Cerebral Arteries | 2 | 2009 | 39 | 0.100 |
Why?
|
Infusions, Intravenous | 3 | 2020 | 164 | 0.090 |
Why?
|
Diagnosis, Differential | 2 | 2019 | 937 | 0.090 |
Why?
|
Retinal Vein | 1 | 2011 | 5 | 0.090 |
Why?
|
Vision, Low | 1 | 2011 | 9 | 0.090 |
Why?
|
Graves Disease | 1 | 2010 | 15 | 0.090 |
Why?
|
Echocardiography | 3 | 2018 | 457 | 0.090 |
Why?
|
Hospital Costs | 1 | 2011 | 119 | 0.090 |
Why?
|
Retinal Vein Occlusion | 1 | 2011 | 18 | 0.090 |
Why?
|
Moyamoya Disease | 1 | 2010 | 10 | 0.090 |
Why?
|
Dyslipidemias | 1 | 2010 | 33 | 0.090 |
Why?
|
Lameness, Animal | 1 | 2010 | 9 | 0.090 |
Why?
|
Proportional Hazards Models | 3 | 2018 | 674 | 0.090 |
Why?
|
Prevalence | 2 | 2020 | 1252 | 0.090 |
Why?
|
Organ Size | 1 | 2010 | 164 | 0.090 |
Why?
|
Horse Diseases | 1 | 2010 | 22 | 0.090 |
Why?
|
Interrupted Time Series Analysis | 2 | 2020 | 27 | 0.090 |
Why?
|
Disease Susceptibility | 1 | 2010 | 157 | 0.090 |
Why?
|
HIV Infections | 1 | 1997 | 913 | 0.080 |
Why?
|
Hemorrhage | 1 | 2012 | 260 | 0.080 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2015 | 724 | 0.080 |
Why?
|
Life Style | 1 | 2011 | 299 | 0.080 |
Why?
|
Antibodies, Monoclonal | 2 | 2004 | 839 | 0.080 |
Why?
|
Antiviral Agents | 1 | 2012 | 313 | 0.080 |
Why?
|
Vasodilator Agents | 1 | 2009 | 63 | 0.080 |
Why?
|
Lipoproteins, HDL | 1 | 2009 | 35 | 0.080 |
Why?
|
Neovascularization, Physiologic | 2 | 2006 | 101 | 0.080 |
Why?
|
Recombinant Proteins | 4 | 2020 | 689 | 0.080 |
Why?
|
Venous Thrombosis | 1 | 2009 | 110 | 0.070 |
Why?
|
Medical History Taking | 1 | 2008 | 65 | 0.070 |
Why?
|
Physical Examination | 1 | 2008 | 104 | 0.070 |
Why?
|
Host-Pathogen Interactions | 2 | 2020 | 241 | 0.070 |
Why?
|
Drug-Related Side Effects and Adverse Reactions | 1 | 2009 | 140 | 0.070 |
Why?
|
Snoring | 1 | 2007 | 8 | 0.070 |
Why?
|
Sleep Stages | 1 | 2007 | 16 | 0.070 |
Why?
|
Neuropharmacology | 1 | 2007 | 1 | 0.070 |
Why?
|
Neuroanatomy | 1 | 2007 | 3 | 0.070 |
Why?
|
Pulmonary Embolism | 1 | 2009 | 170 | 0.070 |
Why?
|
Group Processes | 1 | 2007 | 41 | 0.070 |
Why?
|
Europe | 2 | 2017 | 184 | 0.070 |
Why?
|
Postoperative Period | 1 | 2007 | 127 | 0.070 |
Why?
|
3',5'-Cyclic-GMP Phosphodiesterases | 1 | 2006 | 4 | 0.070 |
Why?
|
Polysomnography | 1 | 2007 | 55 | 0.070 |
Why?
|
Magnetoencephalography | 1 | 2006 | 7 | 0.070 |
Why?
|
Evoked Potentials, Somatosensory | 1 | 2006 | 8 | 0.070 |
Why?
|
Manipulation, Chiropractic | 1 | 2006 | 5 | 0.070 |
Why?
|
Vertebral Artery Dissection | 1 | 2006 | 14 | 0.070 |
Why?
|
Reproducibility of Results | 3 | 2019 | 1561 | 0.060 |
Why?
|
Nerve Regeneration | 1 | 2006 | 31 | 0.060 |
Why?
|
Stem Cell Transplantation | 1 | 2006 | 75 | 0.060 |
Why?
|
Basilar Artery | 1 | 2006 | 30 | 0.060 |
Why?
|
Diabetes Mellitus | 1 | 2010 | 515 | 0.060 |
Why?
|
Postoperative Complications | 1 | 2012 | 1202 | 0.060 |
Why?
|
Carbamazepine | 1 | 2005 | 11 | 0.060 |
Why?
|
Inappropriate ADH Syndrome | 1 | 2005 | 7 | 0.060 |
Why?
|
Canada | 1 | 2005 | 147 | 0.060 |
Why?
|
Sodium | 1 | 2005 | 60 | 0.060 |
Why?
|
Topotecan | 1 | 2025 | 5 | 0.060 |
Why?
|
Neuronal Plasticity | 1 | 2006 | 141 | 0.060 |
Why?
|
Program Evaluation | 1 | 2007 | 470 | 0.060 |
Why?
|
Nitric Oxide Synthase Type II | 1 | 2025 | 70 | 0.060 |
Why?
|
Doxorubicin | 1 | 2025 | 97 | 0.060 |
Why?
|
Molecular Docking Simulation | 1 | 2025 | 73 | 0.060 |
Why?
|
Patient Selection | 3 | 2017 | 464 | 0.060 |
Why?
|
Cardiac Surgical Procedures | 1 | 2007 | 249 | 0.050 |
Why?
|
Protein Structure, Tertiary | 1 | 2025 | 657 | 0.050 |
Why?
|
Practice Guidelines as Topic | 1 | 2007 | 705 | 0.050 |
Why?
|
Disintegrins | 1 | 2022 | 4 | 0.050 |
Why?
|
ADAMTS13 Protein | 1 | 2022 | 6 | 0.050 |
Why?
|
Thrombospondins | 1 | 2022 | 6 | 0.050 |
Why?
|
Rural Health | 1 | 2002 | 15 | 0.050 |
Why?
|
Subacute Care | 1 | 2021 | 9 | 0.050 |
Why?
|
Pilot Projects | 2 | 2021 | 914 | 0.050 |
Why?
|
Delphi Technique | 1 | 2021 | 77 | 0.050 |
Why?
|
Disabled Persons | 1 | 2003 | 187 | 0.040 |
Why?
|
Iran | 1 | 2020 | 6 | 0.040 |
Why?
|
Cell Line, Tumor | 1 | 2025 | 1370 | 0.040 |
Why?
|
Immunohistochemistry | 2 | 2006 | 847 | 0.040 |
Why?
|
Hospital Bed Capacity | 1 | 2020 | 25 | 0.040 |
Why?
|
Retina | 1 | 2021 | 115 | 0.040 |
Why?
|
Placebo Effect | 1 | 2020 | 10 | 0.040 |
Why?
|
Bayes Theorem | 1 | 2020 | 109 | 0.040 |
Why?
|
Health Care Rationing | 1 | 2020 | 21 | 0.040 |
Why?
|
Ethics, Medical | 1 | 2020 | 37 | 0.040 |
Why?
|
Genome-Wide Association Study | 1 | 2021 | 331 | 0.040 |
Why?
|
Health Resources | 1 | 2020 | 87 | 0.040 |
Why?
|
Cause of Death | 1 | 2020 | 210 | 0.040 |
Why?
|
Infection Control | 1 | 2020 | 94 | 0.040 |
Why?
|
Cost of Illness | 1 | 2020 | 156 | 0.040 |
Why?
|
Needs Assessment | 1 | 2020 | 187 | 0.040 |
Why?
|
Angiography | 1 | 2019 | 146 | 0.040 |
Why?
|
Feeding Behavior | 1 | 2021 | 254 | 0.040 |
Why?
|
Neurologic Examination | 1 | 2019 | 52 | 0.040 |
Why?
|
Cerebral Small Vessel Diseases | 1 | 2018 | 7 | 0.040 |
Why?
|
Health Status Disparities | 1 | 2020 | 137 | 0.040 |
Why?
|
Arterial Occlusive Diseases | 1 | 2019 | 71 | 0.040 |
Why?
|
Sex Distribution | 1 | 2019 | 244 | 0.040 |
Why?
|
Age Distribution | 1 | 2019 | 249 | 0.040 |
Why?
|
Administration, Oral | 1 | 2019 | 356 | 0.040 |
Why?
|
Argentina | 1 | 2017 | 7 | 0.040 |
Why?
|
North America | 1 | 2017 | 106 | 0.040 |
Why?
|
Venules | 1 | 1997 | 8 | 0.040 |
Why?
|
Patient Admission | 1 | 2019 | 184 | 0.040 |
Why?
|
Italy | 1 | 2017 | 63 | 0.030 |
Why?
|
Biomedical Research | 1 | 2020 | 256 | 0.030 |
Why?
|
Serum Albumin | 1 | 2017 | 45 | 0.030 |
Why?
|
Latin America | 1 | 2017 | 12 | 0.030 |
Why?
|
Neuropsychological Tests | 1 | 2019 | 371 | 0.030 |
Why?
|
Glasgow Coma Scale | 1 | 2017 | 43 | 0.030 |
Why?
|
Algorithms | 2 | 2016 | 976 | 0.030 |
Why?
|
Disease Management | 1 | 2018 | 221 | 0.030 |
Why?
|
Chi-Square Distribution | 1 | 2017 | 409 | 0.030 |
Why?
|
Socioeconomic Factors | 1 | 2019 | 741 | 0.030 |
Why?
|
Tomography Scanners, X-Ray Computed | 1 | 2016 | 13 | 0.030 |
Why?
|
Intensive Care Units | 1 | 2020 | 423 | 0.030 |
Why?
|
Clinical Decision-Making | 1 | 2017 | 146 | 0.030 |
Why?
|
Non-ST Elevated Myocardial Infarction | 1 | 2016 | 30 | 0.030 |
Why?
|
Angina, Unstable | 1 | 2016 | 56 | 0.030 |
Why?
|
Embolectomy | 1 | 2016 | 15 | 0.030 |
Why?
|
Follow-Up Studies | 3 | 2009 | 2337 | 0.030 |
Why?
|
Rats, Wistar | 2 | 2006 | 179 | 0.030 |
Why?
|
Survival Rate | 1 | 2018 | 802 | 0.030 |
Why?
|
Research Design | 1 | 2019 | 555 | 0.030 |
Why?
|
Observer Variation | 2 | 2006 | 205 | 0.030 |
Why?
|
Health Services Accessibility | 1 | 2020 | 521 | 0.030 |
Why?
|
Longitudinal Studies | 1 | 2019 | 1189 | 0.030 |
Why?
|
Kaplan-Meier Estimate | 1 | 2016 | 396 | 0.030 |
Why?
|
ST Elevation Myocardial Infarction | 1 | 2016 | 73 | 0.030 |
Why?
|
Body Mass Index | 1 | 2019 | 831 | 0.030 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2016 | 114 | 0.030 |
Why?
|
Massachusetts | 1 | 2020 | 2002 | 0.030 |
Why?
|
Information Dissemination | 1 | 2015 | 111 | 0.030 |
Why?
|
Critical Illness | 1 | 2017 | 325 | 0.030 |
Why?
|
Health Education | 1 | 2015 | 182 | 0.030 |
Why?
|
Brain Injuries | 1 | 2014 | 135 | 0.030 |
Why?
|
Rats | 2 | 2006 | 1910 | 0.030 |
Why?
|
Pupil | 1 | 2011 | 9 | 0.020 |
Why?
|
Paresis | 1 | 2010 | 15 | 0.020 |
Why?
|
Confusion | 1 | 2010 | 16 | 0.020 |
Why?
|
Plasmapheresis | 1 | 2010 | 18 | 0.020 |
Why?
|
Antithyroid Agents | 1 | 2010 | 18 | 0.020 |
Why?
|
Toe Phalanges | 1 | 2010 | 3 | 0.020 |
Why?
|
Thyroidectomy | 1 | 2010 | 31 | 0.020 |
Why?
|
Ligaments | 1 | 2010 | 11 | 0.020 |
Why?
|
Tendons | 1 | 2010 | 23 | 0.020 |
Why?
|
Horses | 1 | 2010 | 52 | 0.020 |
Why?
|
Bone Marrow | 1 | 2010 | 177 | 0.020 |
Why?
|
Glucocorticoids | 1 | 2010 | 179 | 0.020 |
Why?
|
Cross-Sectional Studies | 1 | 2015 | 2373 | 0.020 |
Why?
|
Multicenter Studies as Topic | 1 | 2008 | 130 | 0.020 |
Why?
|
Regression Analysis | 1 | 2009 | 485 | 0.020 |
Why?
|
Tadalafil | 1 | 2006 | 2 | 0.020 |
Why?
|
Cyclic Nucleotide Phosphodiesterases, Type 5 | 1 | 2006 | 6 | 0.020 |
Why?
|
Ferrocyanides | 1 | 2006 | 1 | 0.020 |
Why?
|
Anisotropy | 1 | 2006 | 58 | 0.020 |
Why?
|
Nerve Fibers | 1 | 2006 | 29 | 0.020 |
Why?
|
Microcirculation | 1 | 2006 | 52 | 0.020 |
Why?
|
Isoenzymes | 1 | 2006 | 136 | 0.020 |
Why?
|
Multiple Myeloma | 1 | 2011 | 325 | 0.020 |
Why?
|
Cyclic AMP | 1 | 2006 | 142 | 0.020 |
Why?
|
Early Diagnosis | 1 | 2006 | 92 | 0.020 |
Why?
|
Animals | 3 | 2010 | 19651 | 0.020 |
Why?
|
Axons | 1 | 2006 | 118 | 0.020 |
Why?
|
Placebos | 1 | 2005 | 68 | 0.020 |
Why?
|
Data Interpretation, Statistical | 1 | 2006 | 191 | 0.020 |
Why?
|
Endothelial Cells | 1 | 2006 | 173 | 0.010 |
Why?
|
Behavior, Animal | 1 | 2006 | 215 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2008 | 677 | 0.010 |
Why?
|
Decision Making | 1 | 2008 | 395 | 0.010 |
Why?
|
Stem Cells | 1 | 2006 | 255 | 0.010 |
Why?
|
Nervous System | 1 | 2004 | 69 | 0.010 |
Why?
|
Models, Statistical | 1 | 2005 | 298 | 0.010 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2006 | 654 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2006 | 942 | 0.010 |
Why?
|
Blood Glucose | 1 | 2004 | 461 | 0.010 |
Why?
|
Ontario | 1 | 2002 | 43 | 0.010 |
Why?
|
Injections, Intravenous | 1 | 2002 | 155 | 0.010 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2002 | 111 | 0.010 |
Why?
|
Transportation of Patients | 1 | 2002 | 42 | 0.010 |
Why?
|
Linear Models | 1 | 2002 | 402 | 0.010 |
Why?
|
Neurons | 1 | 2006 | 863 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2006 | 2050 | 0.010 |
Why?
|